CareDx sharpens precision medicine focus with $260m Naveris acquisition [Yahoo! Finance]
CareDx, Inc. (CDNA)
Last caredx, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.caredxinc.com
Company Research
Source: Yahoo! Finance
CareDx's deal for the precision oncology diagnostics company is structured with an upfront cash payment of $160m, with the potential for an additional $100m pending revenue milestones. CareDx and Naveris expect the transaction to close in Q3 2026. Naveris's lead product is NavDx, a liquid biopsy platform based on tumour tissue modified viral (TTMV) DNA. The test measures fragments of viral DNA released from tumour tissue into the bloodstream and serves as a biomarker in human papillomavirus (HPV)-driven cancers. Designed for tumour-naïve testing and patient management from diagnosis through post-treatment molecular residual disease (MRD) surveillance, NavDx obtained Medicare coverage in 2023. According to Naveris, the Massachusetts-based company has performed 130,000 commercial tests with NavDx to date. In CareDx's Q1 2026 financials, released on 28 April, the company's testing services segment reported revenue of $91m, corresponding to a 48% year-over-year (YoY) uptick. CareDx
Show less
Read more
Impact Snapshot
Event Time:
CDNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDNA alerts
High impacting CareDx, Inc. news events
Weekly update
A roundup of the hottest topics
CDNA
News
- /C O R R E C T I O N -- Bio-IT World Conference & Expo/ [Yahoo! Finance]Yahoo! Finance
- CareDx (CDNA) had its price target raised by BTIG Research from $26.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- CareDx (CDNA) Q1 2026 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- CareDx (CDNA) Q1 2026 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- CareDx to acquire Naveris in up to $260M oncology diagnostics deal [Seeking Alpha]Seeking Alpha
CDNA
Earnings
- 4/28/26 - Beat
CDNA
Sec Filings
- 4/28/26 - Form S-3ASR
- 4/28/26 - Form 10-Q
- 4/28/26 - Form 8-K
- CDNA's page on the SEC website